154 related articles for article (PubMed ID: 15179321)
21. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
22. A novel indole-3-propanamide exerts its immunosuppressive activity by inhibiting JAK3 in T cells.
Carbonnelle D; Duflos M; Marchand P; Chauvet C; Petit JY; Lang F
J Pharmacol Exp Ther; 2009 Nov; 331(2):710-6. PubMed ID: 19710367
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia.
Uckun FM; Mao C
Curr Pharm Des; 2004; 10(10):1083-91. PubMed ID: 15078143
[TBL] [Abstract][Full Text] [Related]
24. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.
Cetkovic-Cvrlje M; Dragt AL; Vassilev A; Liu XP; Uckun FM
Clin Immunol; 2003 Mar; 106(3):213-25. PubMed ID: 12706408
[TBL] [Abstract][Full Text] [Related]
25. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
Chen C; Lu D; Sun T; Zhang T
Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
[TBL] [Abstract][Full Text] [Related]
26. The Janus kinases (Jaks).
Yamaoka K; Saharinen P; Pesu M; Holt VE; Silvennoinen O; O'Shea JJ
Genome Biol; 2004; 5(12):253. PubMed ID: 15575979
[TBL] [Abstract][Full Text] [Related]
27. T cell development and activation in Jak3-deficient mice.
Baird AM; Thomis DC; Berg LJ
J Leukoc Biol; 1998 Jun; 63(6):669-77. PubMed ID: 9620658
[TBL] [Abstract][Full Text] [Related]
28. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.
Soth M; Hermann JC; Yee C; Alam M; Barnett JW; Berry P; Browner MF; Frank K; Frauchiger S; Harris S; He Y; Hekmat-Nejad M; Hendricks T; Henningsen R; Hilgenkamp R; Ho H; Hoffman A; Hsu PY; Hu DQ; Itano A; Jaime-Figueroa S; Jahangir A; Jin S; Kuglstatter A; Kutach AK; Liao C; Lynch S; Menke J; Niu L; Patel V; Railkar A; Roy D; Shao A; Shaw D; Steiner S; Sun Y; Tan SL; Wang S; Vu MD
J Med Chem; 2013 Jan; 56(1):345-56. PubMed ID: 23214979
[TBL] [Abstract][Full Text] [Related]
29. Jak3-regulated genes: DNA array analysis of concanavalin a-interleukin-2-activated chicken T cells treated with a specific jak3 inhibitor.
Kampa D; Burnside J
J Interferon Cytokine Res; 2002 Sep; 22(9):975-80. PubMed ID: 12396719
[TBL] [Abstract][Full Text] [Related]
30. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
[TBL] [Abstract][Full Text] [Related]
32. T cells from Jak3-deficient mice have intact TCR signaling, but increased apoptosis.
Thomis DC; Lee W; Berg LJ
J Immunol; 1997 Nov; 159(10):4708-19. PubMed ID: 9366394
[TBL] [Abstract][Full Text] [Related]
33. Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1).
Cetkovic-Cvrlje M; Dragt AL; Uckun FM
Arzneimittelforschung; 2003; 53(9):648-54. PubMed ID: 14558439
[TBL] [Abstract][Full Text] [Related]
34. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
Chrencik JE; Patny A; Leung IK; Korniski B; Emmons TL; Hall T; Weinberg RA; Gormley JA; Williams JM; Day JE; Hirsch JL; Kiefer JR; Leone JW; Fischer HD; Sommers CD; Huang HC; Jacobsen EJ; Tenbrink RE; Tomasselli AG; Benson TE
J Mol Biol; 2010 Jul; 400(3):413-33. PubMed ID: 20478313
[TBL] [Abstract][Full Text] [Related]
35. Janus kinases and their role in growth and disease.
Aringer M; Cheng A; Nelson JW; Chen M; Sudarshan C; Zhou YJ; O'Shea JJ
Life Sci; 1999; 64(24):2173-86. PubMed ID: 10374907
[TBL] [Abstract][Full Text] [Related]
36. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
Chang BY; Zhao F; He X; Ren H; Braselmann S; Taylor V; Wicks J; Payan DG; Grossbard EB; Pine PR; Bullard DC
J Immunol; 2009 Aug; 183(3):2183-92. PubMed ID: 19596999
[TBL] [Abstract][Full Text] [Related]
37. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.
Conklyn M; Andresen C; Changelian P; Kudlacz E
J Leukoc Biol; 2004 Dec; 76(6):1248-55. PubMed ID: 15371489
[TBL] [Abstract][Full Text] [Related]
38. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
Dai J; Yang L; Addison G
Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
[TBL] [Abstract][Full Text] [Related]
39. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W; Dusa A; Constantinescu SN
Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
[TBL] [Abstract][Full Text] [Related]
40. Peripheral expression of Jak3 is required to maintain T lymphocyte function.
Thomis DC; Berg LJ
J Exp Med; 1997 Jan; 185(2):197-206. PubMed ID: 9016869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
